AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05070390
Drug: Enlicitide Chloride
RxNorm normalized name: CHLORIDE
DrugBank: Chloride ion (DB14547)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg capsule administered orally
Trial: NCT05288166
Drug: Abemaciclib
RxNorm normalized name: Abemaciclib
DrugBank: Abemaciclib (DB12001)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered orally.
Trial: NCT05288166
Drug: Abiraterone
RxNorm normalized name: ABIRATERONE
DrugBank: Abiraterone (DB05812)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT05288166
Drug: Prednisone or Prednisolone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT05288166
Drug: Placebo for Abemaciclib
DrugBank: Abemaciclib (DB12001)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered orally.
Trial: NCT06388031
Drug: Immune checkpoint inhibitor
RxNorm normalized name: Anti-tim3 checkpoint inhibitor mbg453
DrugBank: Sabatolimab (DB16322)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physician's choice immunotherapy with one of the following every 21 days until disease progression or intolerable toxicity or up to 17 cycles:~* Pembrolizumab 200mg;~* Tislelizumab 200mg;~* Camrelizumab 200mg;~* Toripalimab 240mg.
Trial: NCT06123338
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pembrolizumab will be administered on an every 3-week dosing schedule
Trial: NCT06123338
Drug: Trastuzumab
RxNorm normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Trastuzumab will be administered on an every 3-week dosing schedule
Trial: NCT06123338
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxaliplatin every 3 weeks, +/-7 days
Trial: NCT05227131
Drug: Margetuximab
RxNorm normalized name: Margetuximab
DrugBank: Margetuximab (DB14967)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Margetuximab (15 mg/kg) will be administrated by intravenous infusion on Day 1 of each cycle.
Trial: NCT05227131
Drug: Tucatinib
RxNorm normalized name: Tucatinib
DrugBank: Tucatinib (DB11652)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tucatinib (300 mg) will be administrated orally twice daily (every 12 hours) continuously in 21-day cycles.
Trial: NCT06283121
Drug: toripalimab
RxNorm normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy phase: toripalimab 160mg i.v. D1, 3 weeks per cycle.
Trial: NCT04917627
Drug: Vancomycin
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: one vial of vancomycin (1000 mg ) powder form.
Trial: NCT06461377
Drug: Glucagon-like peptide-1 receptor agonist：Semaglutide
DrugBank: Glucagon (DB00040)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The GLP-1RA intervention group was given subcutaneous injection of GLP-1RA for 3 months, while the control group was not given GLP-1RA intervention
Trial: NCT00037531
Drug: Sirolimus (RAPAMUNE)
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT05259904
Drug: L-citrulline
RxNorm normalized name: L-citrulline
DrugBank: Citrulline (DB00155)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 7 weeks of treatment with 15 g/day of orally administered (powder form mixed with water) L-citrulline
Trial: NCT06274853
Drug: GS-441524
RxNorm normalized name: GS-441524
DrugBank: GS-441524 (DB15686)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral GS-441524 capsules
Trial: NCT04849013
Drug: Mescaline 100mg
RxNorm normalized name: Mescaline
DrugBank: Mescaline (DB19083)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: 100mg Mescaline per os, single dose~Other: Placebo (Capsules containing mannitol looking identical to the other drugs)
Trial: NCT04849013
Drug: Mescaline 200mg
RxNorm normalized name: Mescaline
DrugBank: Mescaline (DB19083)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: 200mg Mescaline per os, single dose~Other: Placebo (Capsules containing mannitol looking identical to the other drugs)
Trial: NCT04849013
Drug: Mescaline 400mg
RxNorm normalized name: Mescaline
DrugBank: Mescaline (DB19083)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: 400mg Mescaline per os, single dose~Other: Placebo (Capsules containing mannitol looking identical to the other drugs)
Trial: NCT04849013
Drug: Mescaline 800mg
RxNorm normalized name: Mescaline
DrugBank: Mescaline (DB19083)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: 800mg Mescaline per os, single dose~Other: Placebo (Capsules containing mannitol looking identical to the other drugs)
Trial: NCT04849013
Drug: Mescaline 800mg + Ketanserin 40mg
RxNorm normalized name: ketanserin
DrugBank: Ketanserin (DB12465)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: 800mg Mescaline per os, single dose~Other: 40mg Ketanserin per os, single dose
Trial: NCT04937829
Drug: BI 1569912
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 1569912
Trial: NCT01469507
Drug: Hyaluronan
RxNorm normalized name: hyaluronan
DrugBank: Hyaluronic acid (DB08818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3 weekly injections
Trial: NCT05536037
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given PO
Trial: NCT06446388
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 130 mg/m2, intravenous infusion, D1, up to 8 cycles.
Trial: NCT06446388
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000 mg/m2 administered as IV infusion on D1/D8 of each cycle.
Trial: NCT06446388
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25 mg/m2, intravenous infusion, D1/D8, up to 8 cycles.
Trial: NCT06446388
Drug: QL1706
RxNorm normalized name: QL1706
DrugBank: QL1706 (DB17562)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/kg, intravenous infusion,D1
Trial: NCT06446388
Drug: Chemotherapy drug
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard chemotherapy recommended by guidelines.
Trial: NCT04737850
Drug: Hetrombopag
RxNorm normalized name: Hetrombopag
DrugBank: Hetrombopag (DB16184)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombopoietin receptor agonist
Trial: NCT05244018
Drug: Vitamin D3 tablets
RxNorm normalized name: vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 tablets 50,000 IU units
Trial: NCT05244018
Drug: Vitamin D tablets
RxNorm normalized name: Calcium With Vitamin D Tablets
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D tablets 5000 units as daily requirements
Trial: NCT05303935
Drug: Quetiapine 50 MG
RxNorm normalized name: quetiapine 50 MG
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A single dose of 50mg of quetiapine taken at bedtime for one night.
Trial: NCT05382156
Drug: Osilodrostat
RxNorm normalized name: osilodrostat
DrugBank: Osilodrostat (DB11837)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: oral administration of Osilodrostat tablets at different doses according to patient's need
Trial: NCT05359068
Drug: Valsartan
RxNorm normalized name: Valsartan
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1 valsartan capsule
Trial: NCT05992428
Drug: DA-8010 5mg
RxNorm normalized name: DAS-181
DrugBank: DAS-181 (DB15313)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[Part 1\] DA-8010 5mg + Paroxetine 20mg \[Part 2\] DA-8010 5mg + Mirabegron 50mg
Trial: NCT05992428
Drug: Paroxetine 20mg
DrugBank: Paroxetine (DB00715)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: \[Part 1\] DA-8010 5mg + Paroxetine 20mg
Trial: NCT05992428
Drug: Mirabegron 50mg
RxNorm normalized name: MIRABEGRON 50MG SA TAB
DrugBank: Mirabegron (DB08893)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: \[Part 2\] DA-8010 5mg + Mirabegron 50mg
Trial: NCT06597019
Drug: Inclisiran
RxNorm normalized name: Inclisiran
DrugBank: Inclisiran (DB14901)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Inclisiran (inclisiran sodium 300 mg subcutaneous (s.c.) for participants with body weight ≥23 kg and inclisiran sodium 180 mg s.c. for participants with body weight \<23 kg. The dose level is based on the participant's body weight on Day 1 (for Part 1) and Day 360 (for Part 2), respectively.
Trial: NCT04682509
Drug: Glecaprevir/pibrentasvir
RxNorm normalized name: GLECAPREVIR/PIBRENTASVIR
DrugBank: Pibrentasvir (DB13878)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Manufacturer is AbbVie, Inc., North Chicago, IL Mavyret® is commercially available and FDA approved for the treatment of HCV genotype 1, 2, 3, 4, 5, or 6 infection in patients without cirrhosis or with compensated cirrhosis and also for the treatment of adult patients with HCV genotype 1 infection who previously have been treated with a regimen containing an HCV NS5A inhibitor or an NS3/4A protease inhibitor. An immediate release bilayer oral tablet containing a fixed-dose combination of 100 mg of glecaprevir and 40 mg of pibrentasvir. The daily dose of glecaprevir/pibrentasvir used will be the standard FDA approved dose: 3 tablets taken once daily (total daily dose: glecaprevir 300 mg and pibrentasvir 120 mg).
Trial: NCT05824494
Drug: Cadonilimab
RxNorm normalized name: Cadonilimab
DrugBank: Cadonilimab (DB16680)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cadonilimab 10mg/kg,every 3 weeks,IV infusion
Trial: NCT05824494
Drug: Nab paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nab paclitaxel ≤260mg/m2,every 3 weeks,IV infusion
Trial: NCT06424717
Drug: Avelumab
RxNorm normalized name: Avelumab
DrugBank: Avelumab (DB11945)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will be administered Avelumab intravenously (IV).
Trial: NCT06424717
Drug: Tuvusertib
RxNorm normalized name: Tuvusertib
DrugBank: Tuvusertib (DB18790)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be administered Tuvusertib orally.
Trial: NCT05176379
Drug: Fluconazole 150 mg
RxNorm normalized name: fluconazole 150 MG
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A single acute 150 mg dose
Trial: NCT06366945
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin AUC 5 on weeks 1, 3, and 6
Trial: NCT06366945
Drug: Tislelizumab
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tislelizumab 200 mg on weeks 3, 6, and 9;if adjuvant immunotherapy is omitted, Tislelizumab will be administered on weeks 1, 3, 6, 9, 12, 15 after surgery
Trial: NCT06366945
Drug: Polymeric Micellar Paclitaxel
RxNorm normalized name: Douxo Micellar
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Polymeric Micellar Paclitaxel 300mg/mg/m2 on weeks 1, 3 and 6
Trial: NCT05151614
Drug: Colchicine 0.5 MG
RxNorm normalized name: colchicine 0.5 MG
DrugBank: Colchicine (DB01394)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Colchicine 0.5 mg tab 1x2 for 1 week then o.5mg tab. 1x1 for another week + the standard therapy ( total duration of colchicine 14 days).
Trial: NCT06443255
Drug: Lidocaine 4%
RxNorm normalized name: Lidocaine 4% Patch
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1.5 mL of 4% lidocaine
Trial: NCT06443255
Drug: Xylometazoline 0.1%
DrugBank: Xylometazoline (DB06694)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.5 mL of xylometazoline 0.1%
Trial: NCT05305768
Drug: IncobotulinumtoxinA
RxNorm normalized name: incobotulinumtoxinA
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Injection of glabellar rhytids
Trial: NCT06319248
Drug: Midodrine
RxNorm normalized name: Midodrine
DrugBank: Midodrine (DB00211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will receive standard of care for sepsis and 10 mg of Midodrine every 8 hours administered orally or enterally (via nasogastric tube)
Trial: NCT05487755
Drug: Tadalafil 20Mg Oral Tablet
RxNorm normalized name: Tadalafil 20mg Oral tablet
DrugBank: Tadalafil (DB00820)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tadalafil is a phosphodiesterase type 5 enzyme (PDE5) inhibitor used mainly in erectile dysfunction and pulmonary hypertension by a mechanism involving increase(NO-cGMP-PKG) signaling pathway.(8) Tadalafil is a powerful pleiotropic drug that it can be used in DN as it can target more than pathway involved in pathogenesis of DN include hyperglycemia and endothelial dysfunction through increase (NO-cGMP) signaling pathway as well as hyperlipidemia
Trial: NCT05487755
Drug: Pentoxifylline 400 MG Oral Tablet
RxNorm normalized name: pentoxifylline 400 MG Oral Tablet
DrugBank: Pentoxifylline (DB00806)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pentoxifylline is a methyl xanthine derivative, non selective phosphodiesterase enzyme inhibitor used mainly to treat peripheral vascular diseases by improve blood flow
Trial: NCT00006143
Drug: Somatropin
RxNorm normalized name: Somatropin
DrugBank: Somatotropin (DB00052)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04387071
Drug: VLP-encapsulated TLR9 Agonist CMP-001
RxNorm normalized name: poly (lactide-co-glycolide)-polyethylene glycol nanoparticles encapsulating quercetin
DrugBank: Quercetin (DB04216)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given SC and IT
Trial: NCT03680976
Drug: CXA-10
RxNorm normalized name: CXA-10
DrugBank: CXA-10 (DB15026)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid-filled capsule containing 150 mg CXA-10 in super refined olive oil.
Trial: NCT04004845
Drug: Cytotec
RxNorm normalized name: Cytotec
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Misoprostol 25mcg vaginal
Trial: NCT04004845
Drug: oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxytocin 10 IU/ml Solution for infusion
Trial: NCT05230810
Drug: Alpelisib
RxNorm normalized name: ALPELISIB
DrugBank: Alpelisib (DB12015)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Orally twice a day
Trial: NCT04565496
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pembrolizumab will be administered at the dose of 200 mg intravenously, every 3 weeks, for a total of 3 cycles prior to RP and ePLND
Trial: NCT05230810
Drug: Tucatinib
RxNorm normalized name: Tucatinib
DrugBank: Tucatinib (DB11652)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Orally once a day
Trial: NCT05230810
Drug: Fulvestrant
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 500 mg intramuscularly into the buttocks slowly~\*Fulvestrant will be administered only in patients with HR+/HER2+ metastatic breast cancer
Trial: NCT04836520
Drug: SHR6390+anatrozole
RxNorm normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SHR6390 is a novel small molecule inhibitor specifically targeting the CDK4/6 pathway.
Trial: NCT06185972
Drug: Definity
RxNorm normalized name: Definity
DrugBank: Perflutren (DB00556)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Stimulation of Definity microbubbles using Sonalleve device within tumour vasculature
Trial: NCT06318871
Drug: Interleukin-2 (IL-2)
RxNorm normalized name: Fusion protein comprised of a circularly-permuted interleukin-2 (IL-2) with the extracellular domain of IL-2 receptor alpha
DrugBank: Human interleukin-2 (DB14865)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interleukin-2 (aldesleukin, IL-2) will be used to support natural killer cell proliferation and activity
Trial: NCT05560555
Drug: Tafamidis
RxNorm normalized name: Tafamidis
DrugBank: Tafamidis (DB11644)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 61 milligrams (mg) as received in studies B3461028 and B3461045
Trial: NCT06121505
Drug: Sintilimab
RxNorm normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive sintilimab combined with standard platinum-based doublet chemotherapy for a total of 4 cycles. Patients subsequently received maintenance treatment with sintilimab, and continued treatment until disease progression (PD), intolerable toxicity, withdrawal of informed consent, initiation of other anti-tumor treatments, death, or other circumstances that should stop treatment as specified in the protocol. Whichever occurs first. The maximum treatment time with sintilimab is 24 months (or 35 cycles).
Trial: NCT04729608
Drug: Batiraxcept
RxNorm normalized name: Batiraxcept
DrugBank: Batiraxcept (DB17522)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Batiraxcept is an experimental drug
Trial: NCT04729608
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel is the standard of care, background therapy
Trial: NCT04649489
Drug: Atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: atezolizumab 1200mg and bevacizumab 15mg/kg
Trial: NCT05291052
Drug: Tislelizumab
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tisleizumab 200 mg intravenously (IV) every 3 weeks (Q3W) ,D1
Trial: NCT05291052
Drug: Lenvatinib
RxNorm normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenvatinib 8 mg (for patient weight \< 60 kg) or 12 mg (for patient weight ≥ 60 kg), orally, QD, D1-21, Q3W
Trial: NCT05291052
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxaliplatin 130 mg/m2, IV， D1，Q3W~Subjects can receive up to 8 cycles of the XELOX regimen (Oxaliplatin and Capecitabine). For subjects who are intolerant to XELOX regimen or have stable disease or objective response after complete 8 cycles of XELOX regimen, treatment with tisleizumab and lenvatinib will be continued until tumor progression or for a maximum of 2 years.
Trial: NCT06173596
Drug: Itraconazole
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive Itraconazole orally.
Trial: NCT06173596
Drug: Fluconazole (AxMP)
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive Fluconazole orally.
Trial: NCT06173596
Drug: Carbamazepine (AxMP)
RxNorm normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive Carbamazepine orally.
Trial: NCT00002194
Drug: Nevirapine
RxNorm normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04877587
Drug: Ascorbate
RxNorm normalized name: ascorbate
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A patient-individualized pharmacokinetically-guided dose escalation design will be used for Ascorbate. The goal of the within-patient dose escalation is to achieve a target plasma ascorbate level between 20mM and 30mM. The administered dose levels under consideration are listed below.~Dose Level Ascorbate~* 2 60 g/m2 IV Days (1,2,8,9,15,16)~* 1 50 g/m2 IV Days (1,2,8,9,15,16) 0 (Starting dose) 40 g/m2 IV Days (1,2,8,9,15,16)~  * 1 30 g/m2 IV Days (1,2,8,9,15,16)
Trial: NCT04877587
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine 900 mg/m2 given at a fixed dose rate of 10 mg/m2/min on D1, D8 and D15 to be given over 90 min every 28 days
Trial: NCT04990102
Drug: CPX-351
RxNorm normalized name: CPX
DrugBank: DPCPX (DB12946)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daunorubicin 8.8mg/m2 + cytarabine 20mg/m2
Trial: NCT05918822
Drug: Maribavir Commercial Tablet Formulation
RxNorm normalized name: maribavir
DrugBank: Maribavir (DB06234)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Maribavir commercial tablet.
Trial: NCT05918822
Drug: Maribavir Pediatric Powder-for-oral Suspension Formulation
RxNorm normalized name: maribavir
DrugBank: Maribavir (DB06234)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Maribavir pediatric powder-for-oral suspension.
Trial: NCT05918822
Drug: Rabeprazole
RxNorm normalized name: Rabeprazole
DrugBank: Rabeprazole (DB01129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rabeprazole tablet.
Trial: NCT05132569
Drug: Tolebrutininb
RxNorm normalized name: Tolebrutinib
DrugBank: Rutin (DB01698)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Film-coated tablet Route of administration: Oral
Trial: NCT05524311
Drug: Baricitinib
RxNorm normalized name: baricitinib
DrugBank: Baricitinib (DB11817)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral tablets (2 mg) will be used For children \> or = 6 years: 4 mg once a day (2 x 2 mg) during the 24 weeks-period study For children \< 6 years: 2 mg once a day during the 24 weeks -period study
Trial: NCT03803111
Drug: Initial FCM
RxNorm normalized name: FCM
DrugBank: Fosfomycin (DB00828)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Initial intravenous iron supplementation (FCM)
Trial: NCT03803111
Drug: Subsequent FCM
RxNorm normalized name: FCM
DrugBank: Fosfomycin (DB00828)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subsequent intravenous iron Supplementation (FCM) after 2 months
Trial: NCT04955366
Drug: Belatacept
RxNorm normalized name: Belatacept
DrugBank: Belatacept (DB06681)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Belatacept is an immunosuppressive medication and will be given as an intravenous infusion at a dose of 5 mg/kg monthly